T cells display the principal characteristics of professional antigen-presenting cells (APCs), in addition to playing a vital role in immunity through cytokine secretion and their cytotoxic activity. However, it is not clear whether T cells perform APC-like functions under pathological conditions. In this study, we showed that, in contrast to peripheral-derived T cells directly isolated from PBMCs of gastric cancer patients, tumor-activated T cells not only killed tumor cells efficiently but also strongly induced primary CD4 + and CD8 + T cells proliferation and differentiation. More importantly, they abrogated the immunosuppression induced by CD4 + CD25 + Treg cells and induced the cytotoxic function of CD8 + T cells from patients with gastric cancer. In conclusion, tumor-activated T cells can induce adaptive immune responses through their APC-like functions, and these cells may be a potentially useful tool in the development of tumor vaccines and immunotherapy.
Introduction

T cells are a distinct subset of CD3
+ T lymphocytes characterized by the presence of T cell receptors (TCRs), which are encoded by V -and V -gene segments [1] . In human peripheral blood, T cells typically represent only 3-5% of all T lymphocytes and are V 2 + T cell subset predominant; however, they are common in the organs and mucosa, and, here, they are V 1 + T cell subset predominant, acting as the first defense system against the entry of foreign organisms. In contrast to conventional T cells, T cells express a limited repertoire of TCR V-region genes. Stimulated T cells undergo activation, which results in a plethora of poorly defined changes, including proliferation, proinflammatory cytokine, and chemokine secretion, and altered cell surface phenotypes [1] . T cells participate in the immune response by direct cytolysis, development of memory phenotypes, and modulation of immune cells, and they have been implicated in autoimmune disorders, immune deficiencies, infections, and tumor diseases.
T cells recognize and kill a range of tumor cells with multiple tissue origins [2, 3] , and the genetic absence of T cells rendered mice significantly more susceptible to tumor growth in vivo [4] [5] [6] . The antitumor properties of T cells have been exploited as a potential target for tumor immunotherapy [2, 7] . It has been reported that the most common subtype of these cells in human blood is V 9V 2, which recognizes a group of nonpeptide phosphoantigens (PAg)-of which isoprenyl pyrophosphate (IPP) has been well characterized-that are known to be upregulated in infection or cancer [8, 9] . Further, PAgs may be presented to -TCRs via a surface molecule (i.e., F1-ATPase) in a manner Journal of Immunology Research somewhat analogous to MHC-mediated antigen presentation [10] , suggesting that V 9V 2 cells can function as professional antigen-presenting cells (APCs) [11] [12] [13] . Human T cells exhibit a potent cytotoxicity against various tumor cells as cytotoxic T cells [2, [14] [15] [16] [17] . However, the significance of T cells expressing the APC-like phenotype and the mechanisms by which they fight tumor cells remains largely unknown. In this study, we showed that T cells from patients with gastric cancer could not only serve as targets for T-mediated antitumor activity but also display the APClike phenotype and functions.
Materials and Methods
Patient Subjects.
Human peripheral blood and fresh tumor tissue samples were obtained from gastric cancer patients (16 men and 4 women; age: 47-69 years; median age: 58.1 ± 6.4 years) newly diagnosed on the basis of clinical history, gastroscopic examination, and pathological diagnosis. Healthy controls (8 men and 2 women; age: 39-63 years; median age: 54.4 ± 8.7 years) were also enrolled, based on normal results from laboratory and physical examinations. Ethics approval for this study was granted by the Ethics Committee of the Affiliated Hospital of Jiangsu University, and written informed consent was obtained from all patients enrolled.
Flow Cytometric Assays. Cells (1 × 10
5 ) were suspended in PBS containing 2% FBS for 10 min to block nonspecific binding sites and then were incubated at 4 ∘ C for 30 min to determine the percentages of subsets of lymphocyte cells with a combination of antibodies as follows: CD3-APC (UCHT1), CD8-PE (B9.11), CD4-FITC (13B8.2), CD80-FITC (MAB104), CD83-PE (HB15a), CD86-PE (HA5.2B7), HLA-DR-PE (IM0464), CD25-PE (B1.49.9), pan -PC5 (IMMU510), and CD45-APC (J33); all were purchased from Beckman Coulter. Cell apoptosis was stained with the Apoptosis Detection Kit I (BD Pharmingen) according to the manufacturer's instructions. For indirect staining, cells were washed twice with PBS and then incubated for 20 min at 4 ∘ C with PE-conjugated goat anti-mouse IgG. Compensation was set up with single-stained samples; low forward scatter elements (RBC and debris) were excluded from analysis, and 10,000 events were collected and analyzed by FACSAria cytometer (BD Biosciences). 
Cell Isolation and
Cytotoxic Assay.
The cytotoxic activity of effector T cells was determined by measuring the amount of lactate dehydrogenase (LDH) released from target cells. The commercial LDH Cytotoxicity kit (Beyotime, China) was used according to the manufacturer's instructions. Maximum LDH release of target cells was determined by lysing target cells for 45 min (lysis buffer provided within the assay) and subsequently measuring the LDH from the culture medium. Absorbance values after the colorimetric reaction were measured at 490 nm with a reference wavelength of 655 nm, using a BioRad Model 550 microplate reader (Bio-Rad, Hercules, CA, USA).
Measurement of Cytokines by ELISA. The supernatants from
T cells culture were collected and stored at −80 ∘ C until analysis. Cytokines of IFN-, IL-1, IL-4, IL-6, IL-10, and IL-12 concentrations were measured using commercial enzyme-linked immunosorbent assay (R&D systems) according to the manufacturer's instructions.
Confocal Microscopy. Tumor cells were labeled with CFSE and incubated with tumor-activated
T cells stained with mouse antihuman HLA-DR-PE-Cy5 before analysis. Images were captured using confocal microscopy (Leica TCS SP5; Leica Microsystems, Bannockburn, IL, USA) using the LAS AF confocal software. Protein antigen capture between cell-cell interactions was visualized using time-lapse confocal microscopy as described previously [19] .
Statistical Analysis.
Unless indicated otherwise, data are expressed as mean ± SD. Comparison between two groups was performed by Student's -tests. Data from more than two groups were compared using one-way ANOVA with the Tukey-Kramer multiple comparison test. < 0.05 was considered statistically significant.
Results
Tumor-Activated T Cells Display Characteristics of APCs.
T cells were directly isolated from the peripheral blood of gastric cancer patients (defined as peripheralderived T cells) and cultured with irradiated autologous PBMCs in the presence of IL-2 and IL-15. The results showed no obvious proliferation of the peripheral-derived T cells. In contrast, when the peripheral-derived T cells were cultured with irradiated autologous tumor cells in the presence of IL-2 and IL-15, they showed markedly increased proliferation (defined as tumor-activated T cells) ( Figure 1 (a); = 9, < 0.01).
To evaluate the potential functions of tumor-activated T cells, we assessed the pattern of surface expression of immune-costimulatory molecules and the profile of cytokines secreted. The results showed no detectable expression of CD80, CD83, or CD86 on the surface of T cells from PBMCs of normal donors (control), peripheralderived T cells, and T cells directly isolated from tumor tissues (defined as tumor tissue-derived T cells). In addition, the antigen-presenting molecule HLA-DR was strongly expressed on T cells, and the expression in cells from patients was higher than that in cells from normal donors. Interestingly, we found that the T cell costimulatory molecules CD80 and CD86 and the mature molecule CD83 were substantially upregulated on the tumor-activated T cells, along with the obvious increased expression of HLA-DR ( Figure 1(b); = 9) . To explore the phenomenon that the factors from tumor tissue alone were particular to induce APC-like phenotypes in autogenetic T cells, a group by using normal T cells activated by tumor tissue was set up. We found that the T cells proliferated but lacked changes of APC-like phenotypes (similar to control), suggesting that the T cell proliferation was caused by an allogeneic response. Taking together, the factors from tumor tissue alone could contribute to induce APC-like phenotypes in autogenetic T cells.
Confocal microscopy results showed that, when T cells from patients were cocultured with autologous tumor cells for 2 h, the antigen component from the tumor cells was colocalized on the T cells ( Figure 1 
Tumor-Activated T Cells Abrogate Immunosuppression Induced by CD4
+ CD25 + Treg Cells. Our previous study demonstrated that CD4 + CD25 + Treg cells isolated from tumor patients inhibited the proliferation of autologous effector CD4 + T cells [20] . 
Tumor-Activated T Cells Not Only Directly Kill Tumor Cells but Also Activate the Cytotoxic Effects of Autologous
Discussion
In general, APCs such as dendritic cells (DCs) sample Ags from target cells or pathogens by phagocytosis and then present or cross-present processed Ags to MHC class II I molecules, to trigger adaptive immune responses by the release of cytokines, expression of costimulatory molecules, and Ag stimulation [12] . On the one hand, T cells display characteristics of adaptive immunity, wherein they express a rearranged TCR receptor, generate immunologic memory, and transform into cytotoxic T lymphocytes. On the other, they may also be considered part of the innate immune system, since they respond rapidly to antigenic stimuli, have limited TCR gene usage, and express pattern-recognition receptors [13] . To our knowledge, the present study is the first to identify an APC-like function for T cells in tumor patients.
Previous studies demonstrated that human T cells from tonsillar tissue have APC functions, efficiently crosspresenting soluble proteins to effector CD8 + T cells and inducing effector cells differentiation and activation [1, 11, 21] . However, these results were acquired using T cells stimulated by the isoprenoid metabolite isopentenyl pyrophosphate (IPP) in vitro, and whether T cells function like APCs under different disease circumstances, particularly tumors remained largely unknown. In the present study, peripheral-derived T cells from gastric cancer patients were used. Our findings showed that these peripheral-derived T cells were activated and proliferated when stimulated by autologous tumor cells in vitro, suggesting that tumor cells were equipped with the signals to activate peripheralderived T cells. The underlying mechanism is not clear at present. We previously found that that autologous tumor cells selectively expanded T cells among CD4 − CD8 − PBMCs from cancer patients and this phenomenon was related to TCR and NKG2D signals.
Accumulating experimental and clinical data indicate that T cells can recognize aminobisphosphonates and phosphorylated intermediates of the bacterial nonmevalonate isoprenoid pathway, known as phosphoantigens. In addition, high concentrations of IPP, possibly generated because of a dysregulated mevalonate pathway as well as ectopically expressed mitochondrial F1-ATPase/apolipoprotein I complex on malignant cells, can selectively induce T cell expansion through the TCR pathway [3, 8, 22] . NKG2D recognizes the stress-inducible MHC class I-related chains A and B (MIC A/B) and glycophosphatidylinositollinked proteins UL16-binding proteins (ULBPs), which are expressed by many tumor cells [23] [24] [25] [26] [11, 19, 27] . However, our understanding of the APC effects of T cells on T cell differentiation is currently rudimentary. Our results showed that peripheral-derived T cells have no APC-like functions, which exclude their involvement in + T cells, possibly through an unknown antigen-presenting pathway, proinflammatory cytokines, and costimulator molecules. These functions are highly beneficial, and T cells are a unique and conserved population of lymphocytes that have been the subject of a recent explosion of interest owing to their essential contributions to many types of immune responses and immunopathology [28] . The functional difference between peripheral-derived and tumoractivated T cells is ascribed to the suppressive state of the immune system in cancer patients.
Considerable attention in immunotherapy research is currently focused on human T cells because of their functional uniformity [29] . The role of T cells in oncology is concentrated around their potential applications in cancer treatment, for direct cytolysis. In terms of cellular immunotherapy, it may be important to emphasize that T cell differentiation induced by T cells leads to CD4 + T helper cell and effector CD8 + T cell responses. Further, experimental and clinical data indicate that T cells exhibit a potent HLA-unrestricted lytic activity against various tumor cell lines and display antitumor effects [17, 30, 31] . In addition to TCR-dependent recognition, activation of the killer receptor NKG2D is involved in the cytotoxic activity of T cells. In general, the cytotoxicity of T cells to tumor cells involves the TCR and NKG2D receptors and depends on the perforin/granzyme pathway.
Our results also suggested that tumor-activated T cells directly lyse the target tumor cells and trigger the activation and functioning of CD4 + and CD8 + T cells. Of note, the molecular mechanisms underlying T cellmediated activation of conventional CD4 + or CD8 + T cells are similar to those employed by professional APCs, which involve TCR signals and the costimulatory molecules CD80/CD86. Therefore, a possible mechanism for the APClike behavior of tumor-activated T cells is that these cells are loaded with tumor components for a brief period, during which they process and express costimulatory molecules CD80/CD86. The recognition of tumor cells by T cells does not depend on MHC-mediated Ag presentation, which may represent a key advantage in immunotherapy during advanced stages of cancer [32] .
It is well established that the aggregation of CD4 + CD25 + Treg cells in the tumor milieu is involved in the immune escape of tumors and is detrimental for immunotherapy among tumor patients [20, 33, 34] . Further, an interaction between CD4 + CD25 + Treg cells and T cells has been reported [35] . Recent data have further shown that T cells from tumor tissues are positively correlated with Foxp3 + suppressive T cells in advanced breast tumors and inversely correlated with relapse-free and overall survival of breast cancer patients [36] . These findings raise interesting questions on whether tumor-activated T cells are capable of weakening [22, 37, 38] , and, thus, these cells may become a continual and renewable source of functional APCs. They may be used to produce tumor vaccines to induce an adaptive immune response against tumors. We believe that T cells will play a key role in developing cancer immunotherapy strategies.
